NBIX:NASDAQ
Neurocrine Biosciences
142,44 US$
arrow_upward
+0,84%(+1,19) 1 d
142,44 US$
0,00% (0,00)
bedtimeFuera de horario
Cerrado: 9 oct, 16:00:00 GMT-4 · USD
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de NBIX...
Abrir
141,33 US$
Alto
143,55 US$
Bajo
140,02 US$
Cap. burs.
14,48 mil M
Vol. medio
1,28 M
Volumen
1,02 M
Ratio PER
20,88
Máximo en 52 sem.
186,12 US$
Mínimo en 52 sem.
122,14 US$
BPA
6,82 US$
Beta
0,40
Acciones en circulación
101,65 M
N.º de empleados
2 mil
Abrir
141,33 US$
Alto
143,55 US$
Bajo
140,02 US$
Cap. burs.
14,48 mil M
Vol. medio
1,28 M
Volumen
1,02 M
Ratio PER
20,88
Máximo en 52 sem.
186,12 US$
Mínimo en 52 sem.
122,14 US$
BPA
6,82 US$
Beta
0,40
Acciones en circulación
101,65 M
N.º de empleados
2 mil
Noticias
De fuentes web y partners de noticias
Zacks
·
hace 6 horas
4 CNS Drug Stocks Worth Watching This World Mental Health Day
Simply Wall Street
·
hace 1 día
How Investors Are Reacting To Neurocrine Biosciences (NBIX) New VYKAT XR Data
Perfil
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Acerca de Neurocrine Biosciences
CEOKevin C. Gorman
Empleados2,5 mil
Fundación1992
SedeSan Diego, California, Estados Unidos
Sector-
Sitio webneurocrine.com